Compare FGBI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | SPRO |
|---|---|---|
| Founded | 1934 | 2013 |
| Country | United States | United States |
| Employees | 346 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 135.5M |
| IPO Year | N/A | 2017 |
| Metric | FGBI | SPRO |
|---|---|---|
| Price | $9.49 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.7K | ★ 405.8K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | $17.10 |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $4.31 | $0.65 |
| 52 Week High | $10.08 | $3.09 |
| Indicator | FGBI | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 48.31 |
| Support Level | $9.32 | $2.15 |
| Resistance Level | $10.03 | $2.70 |
| Average True Range (ATR) | 0.45 | 0.11 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 63.58 | 28.16 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.